Suven Life Sciences announces today that the grant of one product patent from Norway, one product patent from South Korea and one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027, 2034 and 2036 respectively.

The granted claims of the patents include the class of selective 5-HT6 and 5HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 2.8, or 1.65%, to trade at  Rs 172.00.  The total volume of shares traded  was  30,246 at the BSE (12.11 p.m., Thursday).